Diabetes. Type 2 diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group receive a 500 mg capsule of herbal drug two times a day. Intervention 2: Control group: Patients in this group receive a 500 mg capsule of pl
Sponsors
Iranian academic center for education culture and research
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 60 Years
Inclusion criteria
Inclusion criteria: Diabetic patients treated with Dietary and hypoglycemic agents Blood HbA1c level 7.5-8.5 % Fasting blood glucose levels between 130 to 170 mg/dL Have diabetes for at least two years 40 to 60 years old
Exclusion criteria
Exclusion criteria: Patient with renal, hepatic and cardiac failure Patients with diabetic foot ulcer, gangrene, or any severe illness Painful diabetic neuropathy and depressed patients Smokers and alcoholic patients Patients who tend to change their exercise program or diet
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting blood glucose. Timepoint: Baseline and after 3 months at end of the study. Method of measurement: Blood Test.;HbA1C. Timepoint: Baseline and after 3 months at end of the study. Method of measurement: Blood Test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Cholesterol. Timepoint: Baseline and after 3 months at end of the study. Method of measurement: Blood Test.;Triglycerid. Timepoint: Baseline and after 3 months at end of the study. Method of measurement: Blood Test.;Low-density lipoprotein. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood low-density lipoprotein level will be determined in laboratory by commercially available.;High-density lipoprotein. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood High-density lipoprotein level will be determined in laboratory by commercially available kit.;Aspartate aminotransferase. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood aspartate aminotransferase level will be determined in laboratory by commercially available kit.;Alanine aminotransferase. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood alanine aminotransferase level will be determined in laboratory by commercially available kit.;Blood urea nitrogen. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood blood urea nitrogen level will be determined in laboratory by commercially available kit.;Creatinine. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood creatinine level will be determined in laboratory by commercially available kit.;Alkalin phosphatase. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood Alkalin phosphatase level will be determined in laboratory by commercially available kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZhila Taherzadeh
Mashhad University of Medical Sciences
Outcome results
None listed